Company news
Allergy Therapeutics Plc (LSE:AGY) news
Allergy Therapeutics Plc news releases on 6ix. Latest, Feb 2, 2018: Hardman Research: Growth in a tough market
Press releases — page 5
Hardman Research: Growth in a tough market
February 2, 2018
PQ Birch Phase III trial completes recruitment
January 9, 2018
Co-development agreement with Ergomed plc
December 12, 2017
Block Listing Application
November 21, 2017
Allergy Therapeutics to Present at Jefferies 2017
November 13, 2017
Publication of Annual Report and notice of AGM
October 19, 2017
Commencement of dosing in PQ Grass Phase II Trial
October 19, 2017
Hardman Research: Continuing to gain market share
October 10, 2017
Approval for PQ Grass Phase II trial
September 18, 2017
Expansion of Clinical Development and R&D teams
September 11, 2017
Publication of adjuvant studies in journals
July 6, 2017
Investor and analyst site visits
June 27, 2017
Satellite Symposium at EAACI 2017
June 19, 2017
Directorate changes
June 6, 2017
Issue of Equity
April 13, 2017
Hardman Research: Development across portfolio
April 5, 2017
Interim Results for six months ended 31 Dec 2016
March 29, 2017
First Patient in Pivotal Phase III Birch Study
March 16, 2017
Notice of Interim Results
March 9, 2017
House Dust Mite Allergy Vaccine Gains CTA Approval
February 14, 2017
Positive Efficacy & Safety Data in Peanut Vaccine
February 1, 2017
Hardman Research: Investment driving market share
January 20, 2017
Grant of Awards
December 30, 2016
EU Patent Office grants patent for MCT
November 2, 2016
Issue of equity in respect of exercise of options
October 27, 2016
New data from novel adjuvant system
October 10, 2016
Hardman Research: Performance drives market share
September 26, 2016
Allergy Therapeutics Preliminary Results
September 26, 2016
Notice of Preliminary Results
September 5, 2016
Results of mite immunotherapy Acarovac PlusT
July 8, 2016
Findings from mEEC dose range finding study G204
June 27, 2016
Allergy hosts Satellite Symposium at EAACI
June 13, 2016
Appointment of Finance Director
June 10, 2016
Positive Phase II Data
May 9, 2016
Issue of equity in respect of options exercise
March 23, 2016
Grant of Options under Long Term Incentive Plan
March 11, 2016
Interim Results for the six months ended 31/12/15
March 8, 2016
Hardman & Co Research Report: Development Progress
February 24, 2016
Patient enrolment completed in US Phase IIb study
February 18, 2016
US Phase II study for GrassMATAMPL initiated
December 7, 2015
PQBirch204 Phase II study update
November 30, 2015
Results of Placing
November 17, 2015
Proposed placing to raise up to £12 million
November 17, 2015
World Vaccine Congress Presentation
November 4, 2015
Hardman & Co issues research report
October 21, 2015
Final Results
September 21, 2015
First patient recruited in PQ Birch dose study
September 1, 2015
Key paper published in the World Allergy Journal
August 10, 2015
Director Share Dealings
July 27, 2015
Notice of Results and Trading Update
July 23, 2015